Advances in our understanding of molecular genetics bring about unique challenges in our ability to practice molecular medicine. With the availability of commercial testing for various genetic cancer syndromes, including hereditary melanoma, specific issues regarding its use and limitations require attention before full translation of this tool into the clinical setting.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of the American Academy of Dermatology|
|State||Published - Nov 2004|
Bibliographical noteFunding Information:
Supported by the Dermatology Foundation and in part by grants from the American Skin Association (Dr Tsao) and National Institutes of Health (Dr Tsao).
Copyright 2018 Elsevier B.V., All rights reserved.